MCRB
Seres Therapeutics, Inc.
Price Chart
Latest Quote
$5.33
+0.15 (+2.90%)
Current Price
| Previous Close | $5.18 |
| Open | $5.13 |
| Day High | $5.69 |
| Day Low | $5.13 |
| Volume | 56,060 |
Stock Information
| Shares Outstanding | 9.68M |
| Total Debt | $80.50M |
| Cash Equivalents | $29.83M |
| Revenue | $1.15M |
| Net Income | $-46.90M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $51.62M |
| EPS (TTM) | $-5.20 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $102.28M |
| Sales | $1.15M |
| Income | $-46.90M |
| Book/sh | $2.76 |
| Cash/sh | $3.08 |
| Employees | 66 |
Financial Ratios
| Quick Ratio | 1.55 |
| Current Ratio | 1.65 |
| Debt/Eq | 303.78 |
Returns & Margins
| ROA | -38.88% |
| ROE | -121.87% |
| Operating Margin | -5839.94% |
Ownership
| Insider Ownership | 11.78% |
| Institutional Ownership | 24.37% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.81 |
| P/S | 45.00 |
| P/B | 1.93 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $17.00 |
Technical Indicators
| SMA20 | $6.76 |
| SMA50 | $7.03 |
| SMA200 | $12.00 |
| RSI | 32.00 |
| ATR | 0.6164 |
| Shares Float | 8.47M |
| Short Float | 2.13% |
| Short Ratio | 1.41 |
| Volatility | 0.10 |
| Rel Volume | 0.42 |
Performance History
| Week | -12.77% |
| Month | -10.72% |
| Quarter | -39.64% |
| 6 Months | -66.85% |
| YTD | -64.82% |
| Year | -61.85% |
| 3 Years | -94.21% |
| 5 Years | -98.75% |
| 10 Years | -99.20% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $5.33 | 56,400 |
| 2026-07-16 | $5.18 | 84,100 |
| 2026-07-15 | $5.45 | 30,900 |
| 2026-07-14 | $5.34 | 223,200 |
| 2026-07-13 | $5.62 | 333,700 |
| 2026-07-10 | $6.11 | 154,400 |
| 2026-07-09 | $6.74 | 121,900 |
| 2026-07-08 | $7.14 | 258,100 |
| 2026-07-07 | $8.14 | 98,800 |
| 2026-07-06 | $7.71 | 31,100 |
| 2026-07-02 | $7.74 | 130,800 |
| 2026-07-01 | $7.94 | 150,900 |
| 2026-06-30 | $7.89 | 113,800 |
| 2026-06-29 | $7.79 | 131,500 |
| 2026-06-26 | $7.08 | 301,500 |
| 2026-06-25 | $6.84 | 119,900 |
| 2026-06-24 | $6.81 | 48,900 |
| 2026-06-23 | $7.05 | 75,200 |
| 2026-06-22 | $6.60 | 81,600 |
| 2026-06-18 | $6.61 | 124,600 |
About Seres Therapeutics, Inc.
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
đ° Latest News
Seres Therapeuticsâ SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Study
MarketBeat âĸ 2026-07-10T18:02:07Z
We're A Little Worried About Seres Therapeutics' (NASDAQ:MCRB) Cash Burn Rate
Simply Wall St. âĸ 2026-06-13T12:57:11Z
Seres Therapeutics: Q4 Earnings Snapshot
Associated Press Finance âĸ 2026-03-12T11:23:45ZSector Update: Health Care Stocks Rise Late Afternoon
MT Newswires âĸ 2026-02-12T20:55:37ZSeres to lay off staff, pause top program in latest reboot
BioPharma Dive âĸ 2026-02-12T12:00:00Z
3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround
Zacks âĸ 2025-12-29T15:15:00Z
All You Need to Know About Seres Therapeutics (MCRB) Rating Upgrade to Buy
Zacks âĸ 2025-09-09T16:00:01Z
Seres Therapeutics (MCRB)'s Technical Outlook is Bright After Key Golden Cross
Zacks âĸ 2025-08-28T13:55:02Z
Nxera debuts an obesity pipeline; BridgeBio battles Alnylam for market share
BioPharma Dive âĸ 2025-08-06T11:30:00Z
Seres Therapeutics: Q2 Earnings Snapshot
Associated Press Finance âĸ 2025-08-06T11:15:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $6,544,000 | $3,532,000 | $0 | $0 |
| Cost Of Revenue | $6,544,000 | $3,532,000 | $0 | $0 |
| Total Revenue | $789,000 | $0 | $0 | $0 |
| Operating Revenue | $789,000 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $0 | $0 | $2,468,000 | $6,020,000 |
| Total Expenses | $94,760,000 | $121,315,000 | $195,097,000 | $179,914,000 |
| Other Income Expense | $97,440,000 | $-8,423,000 | $134,000 | $-705,000 |
| Other Non Operating Income Expenses | $16,755,000 | $-14,107,000 | $134,000 | $-705,000 |
| Net Non Operating Interest Income Expense | $2,227,000 | $3,967,000 | $4,833,000 | $-2,962,000 |
| Interest Expense Non Operating | $0 | $0 | $2,468,000 | $6,020,000 |
| Operating Expense | $88,216,000 | $117,783,000 | $195,097,000 | $179,914,000 |
| General And Administrative Expense | $39,156,000 | $53,183,000 | $77,500,000 | $70,263,000 |
| Other Operating Expenses | - | - | $704,000 | $1,004,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $5,696,000 | $-125,771,000 | $-190,130,000 | $-183,581,000 |
| Net Interest Income | $2,227,000 | $3,967,000 | $4,833,000 | $-2,962,000 |
| Interest Income | $2,227,000 | $3,967,000 | $7,301,000 | $3,058,000 |
| Normalized Income | $-74,989,000 | $-131,455,000 | $-190,130,000 | $-183,581,000 |
| Net Income From Continuing And Discontinued Operation | $5,696,000 | $136,000 | $-113,724,000 | $-250,157,000 |
| Total Operating Income As Reported | $-93,971,000 | $-121,315,000 | $-195,097,000 | $-179,914,000 |
| Net Income Common Stockholders | $5,696,000 | $136,000 | $-113,724,000 | $-250,157,000 |
| Net Income | $5,696,000 | $136,000 | $-113,724,000 | $-250,157,000 |
| Net Income Including Noncontrolling Interests | $5,696,000 | $136,000 | $-113,724,000 | $-250,157,000 |
| Net Income Discontinuous Operations | $0 | $125,907,000 | $76,406,000 | $-66,576,000 |
| Net Income Continuous Operations | $5,696,000 | $-125,771,000 | $-190,130,000 | $-183,581,000 |
| Pretax Income | $5,696,000 | $-125,771,000 | $-190,130,000 | $-183,581,000 |
| Special Income Charges | $80,685,000 | $5,684,000 | $0 | $0 |
| Interest Income Non Operating | $2,227,000 | $3,967,000 | $7,301,000 | $3,058,000 |
| Operating Income | $-93,971,000 | $-121,315,000 | $-195,097,000 | $-179,914,000 |
| Gross Profit | $-5,755,000 | $-3,532,000 | $0 | $0 |
| Per Share | ||||
| Diluted EPS | $0.64 | $0.00 | $-17.77 | $-46.20 |
| Basic EPS | $0.64 | $0.00 | $-17.77 | $-46.20 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-70,856,000 | $-125,987,000 | $-181,419,000 | $-170,932,000 |
| Total Unusual Items | $80,685,000 | $5,684,000 | $0 | $0 |
| Total Unusual Items Excluding Goodwill | $80,685,000 | $5,684,000 | $0 | $0 |
| Reconciled Depreciation | $4,133,000 | $5,468,000 | $6,243,000 | $6,629,000 |
| EBITDA (Bullshit earnings) | $9,829,000 | $-120,303,000 | $-181,419,000 | $-170,932,000 |
| EBIT | $5,696,000 | $-125,771,000 | $-187,662,000 | $-177,561,000 |
| Diluted Average Shares | $8,869,742 | $7,769,910 | $6,400,339 | $5,403,852 |
| Basic Average Shares | $8,858,975 | $7,769,910 | $6,400,339 | $5,403,852 |
| Diluted NI Availto Com Stockholders | $5,696,000 | $136,000 | $-113,724,000 | $-250,157,000 |
| Gain On Sale Of Business | $80,685,000 | $5,684,000 | $0 | $0 |
| Research And Development | $49,060,000 | $64,600,000 | $117,597,000 | $109,651,000 |
| Selling General And Administration | $39,156,000 | $53,183,000 | $77,500,000 | $70,263,000 |
| Other Gand A | $24,743,000 | $30,504,000 | $77,500,000 | $70,263,000 |
| Salaries And Wages | $14,413,000 | $22,679,000 | $36,629,000 | $31,277,000 |
| Restructuring And Mergern Acquisition | - | - | - | - |
Fetched: 2026-07-05
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $44,218,000 | $13,784,000 | $-44,856,000 | $10,783,000 |
| Total Assets | $138,193,000 | $139,810,000 | $358,600,000 | $348,784,000 |
| Total Non Current Assets | $88,817,000 | $101,136,000 | $183,190,000 | $154,020,000 |
| Other Non Current Assets | $8,699,000 | $8,699,000 | $75,159,000 | $20,051,000 |
| Current Assets | $49,376,000 | $38,674,000 | $175,410,000 | $194,764,000 |
| Other Current Assets | $3,093,000 | $3,130,000 | $8,049,000 | $13,423,000 |
| Receivables | $517,000 | $4,751,000 | $0 | $0 |
| Accounts Receivable | $517,000 | $2,068,000 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $45,766,000 | $30,793,000 | $127,965,000 | $181,341,000 |
| Cash And Cash Equivalents | $45,766,000 | $30,793,000 | $127,965,000 | $163,030,000 |
| Assets Held For Sale Current | - | $0 | $39,396,000 | - |
| Other Receivables | - | $2,683,000 | - | - |
| Inventory | - | - | $29,647,000 | $0 |
| Investmentin Financial Assets | - | - | - | $0 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $82,966,000 | $91,640,000 | $198,783,000 | $162,590,000 |
| Long Term Debt And Capital Lease Obligation | $72,576,000 | $82,966,000 | $193,196,000 | $158,533,000 |
| Current Debt And Capital Lease Obligation | $10,390,000 | $8,674,000 | $5,587,000 | $4,057,000 |
| Long Term Debt | - | - | $101,544,000 | $50,591,000 |
| Current Debt | - | - | - | $456,000 |
| Other Current Borrowings | - | - | - | $456,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $93,975,000 | $126,026,000 | $403,456,000 | $338,001,000 |
| Total Non Current Liabilities Net Minority Interest | $74,653,000 | $84,804,000 | $304,797,000 | $252,405,000 |
| Other Non Current Liabilities | $2,077,000 | $1,838,000 | $1,628,000 | $1,442,000 |
| Current Liabilities | $19,322,000 | $41,222,000 | $98,659,000 | $85,596,000 |
| Payables And Accrued Expenses | $8,932,000 | $32,548,000 | $26,150,000 | $77,280,000 |
| Payables | $1,682,000 | $4,079,000 | $3,641,000 | $52,210,000 |
| Accounts Payable | $1,682,000 | $4,079,000 | $3,641,000 | $17,440,000 |
| Liabilities Heldfor Sale Non Current | - | $0 | $109,427,000 | - |
| Derivative Product Liabilities | - | $0 | $546,000 | $0 |
| Non Current Deferred Liabilities | - | - | $95,364,000 | $92,430,000 |
| Other Current Liabilities | - | - | $66,922,000 | $34,770,000 |
| Current Deferred Liabilities | - | - | $7,730,000 | $4,259,000 |
| Equity | ||||
| Common Stock Equity | $44,218,000 | $13,784,000 | $-44,856,000 | $10,783,000 |
| Total Equity Gross Minority Interest | $44,218,000 | $13,784,000 | $-44,856,000 | $10,783,000 |
| Stockholders Equity | $44,218,000 | $13,784,000 | $-44,856,000 | $10,783,000 |
| Retained Earnings | $-972,403,000 | $-978,099,000 | $-978,235,000 | $-864,511,000 |
| Gains Losses Not Affecting Retained Earnings | - | - | $0 | $-12,000 |
| Other Equity Adjustments | - | - | - | $-12,000 |
| Other | ||||
| Ordinary Shares Number | $9,556,446 | $8,650,409 | $6,752,073 | $6,261,113 |
| Share Issued | $9,556,446 | $8,650,409 | $6,752,073 | $6,261,113 |
| Tangible Book Value | $44,218,000 | $13,784,000 | $-44,856,000 | $10,783,000 |
| Invested Capital | $44,218,000 | $13,784,000 | $56,688,000 | $61,830,000 |
| Working Capital | $30,054,000 | $-2,548,000 | $76,751,000 | $109,168,000 |
| Capital Lease Obligations | $82,966,000 | $91,640,000 | $97,239,000 | $111,543,000 |
| Total Capitalization | $44,218,000 | $13,784,000 | $56,688,000 | $61,374,000 |
| Additional Paid In Capital | $1,016,611,000 | $991,874,000 | $933,244,000 | $875,181,000 |
| Capital Stock | $10,000 | $9,000 | $135,000 | $125,000 |
| Common Stock | $10,000 | $9,000 | $135,000 | $125,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $72,576,000 | $82,966,000 | $91,652,000 | $107,942,000 |
| Current Capital Lease Obligation | $10,390,000 | $8,674,000 | $5,587,000 | $3,601,000 |
| Current Accrued Expenses | $7,250,000 | $28,469,000 | $22,509,000 | $25,070,000 |
| Net PPE | $80,118,000 | $92,437,000 | $108,031,000 | $133,969,000 |
| Accumulated Depreciation | $-56,613,000 | $-53,196,000 | $-49,078,000 | $-45,040,000 |
| Gross PPE | $136,731,000 | $145,633,000 | $157,109,000 | $179,009,000 |
| Leases | $30,954,000 | $30,954,000 | $32,489,000 | $32,474,000 |
| Construction In Progress | $861,000 | $861,000 | $1,114,000 | $3,970,000 |
| Other Properties | $96,335,000 | $105,371,000 | $115,082,000 | $135,517,000 |
| Machinery Furniture Equipment | $8,581,000 | $8,447,000 | $8,424,000 | $7,048,000 |
| Properties | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | - | - | $95,364,000 | $92,430,000 |
| Current Deferred Revenue | - | - | $7,730,000 | $4,259,000 |
| Dueto Related Parties Current | - | - | $28,053,000 | $34,770,000 |
| Finished Goods | - | - | $0 | $0 |
| Work In Process | - | - | $25,221,000 | $0 |
| Raw Materials | - | - | $4,426,000 | $0 |
| Duefrom Related Parties Current | - | - | $8,674,000 | $0 |
| Other Short Term Investments | - | - | $0 | $18,311,000 |
| Investments And Advances | - | - | - | $0 |
| Available For Sale Securities | - | - | - | - |
Fetched: 2026-07-05
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $865,000 | $-148,989,000 | $-125,329,000 | $-238,637,000 |
| Operating Activities | ||||
| Operating Cash Flow | $1,117,000 | $-148,609,000 | $-117,354,000 | $-228,816,000 |
| Cash Flow From Continuing Operating Activities | $1,117,000 | $-148,609,000 | $-117,354,000 | $-228,816,000 |
| Operating Gains Losses | $-192,000 | $-123,585,000 | $71,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-252,000 | $-380,000 | $-7,975,000 | $-9,821,000 |
| Investing Cash Flow | $-42,000 | $142,293,000 | $10,582,000 | $82,428,000 |
| Cash Flow From Continuing Investing Activities | $-42,000 | $142,293,000 | $10,582,000 | $82,428,000 |
| Net Other Investing Changes | - | $1,401,000 | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $13,167,000 | $23,530,000 | $18,159,000 | $101,168,000 |
| Financing Cash Flow | $13,898,000 | $-90,372,000 | $71,705,000 | $129,602,000 |
| Cash Flow From Continuing Financing Activities | $13,898,000 | $-90,372,000 | $71,705,000 | $129,602,000 |
| Net Common Stock Issuance | $13,167,000 | $23,530,000 | $18,159,000 | $101,168,000 |
| Common Stock Issuance | $13,167,000 | $23,530,000 | $18,159,000 | $101,168,000 |
| Net Other Financing Charges | - | $13,516,000 | - | - |
| Other | ||||
| Repayment Of Debt | $0 | $-127,905,000 | $-52,860,000 | $-1,907,000 |
| Issuance Of Debt | $0 | $0 | $103,378,000 | $27,606,000 |
| Interest Paid Supplemental Data | $0 | $10,858,000 | $12,547,000 | $4,926,000 |
| End Cash Position | $54,434,000 | $39,461,000 | $136,150,000 | $171,215,000 |
| Beginning Cash Position | $39,461,000 | $136,150,000 | $171,215,000 | $188,002,000 |
| Effect Of Exchange Rate Changes | $0 | $-1,000 | $2,000 | $-1,000 |
| Changes In Cash | $14,973,000 | $-96,688,000 | $-35,067,000 | $-16,786,000 |
| Proceeds From Stock Option Exercised | $731,000 | $487,000 | $3,028,000 | $2,735,000 |
| Net Issuance Payments Of Debt | $0 | $-127,905,000 | $50,518,000 | $25,699,000 |
| Net Long Term Debt Issuance | $0 | $-127,905,000 | $50,518,000 | $25,699,000 |
| Long Term Debt Payments | $0 | $-127,905,000 | $-52,860,000 | $-1,907,000 |
| Long Term Debt Issuance | $0 | $0 | $103,378,000 | $27,606,000 |
| Net Investment Purchase And Sale | $0 | $0 | $18,557,000 | $92,249,000 |
| Sale Of Investment | $0 | $0 | $22,983,000 | $140,470,000 |
| Purchase Of Investment | $0 | $0 | $-4,426,000 | $-48,221,000 |
| Net Business Purchase And Sale | $0 | $141,272,000 | $0 | $0 |
| Sale Of Business | $0 | $141,272,000 | $0 | $0 |
| Net PPE Purchase And Sale | $-42,000 | $-380,000 | $-7,975,000 | $-9,821,000 |
| Sale Of PPE | $210,000 | $0 | $0 | - |
| Purchase Of PPE | $-252,000 | $-380,000 | $-7,975,000 | $-9,821,000 |
| Change In Working Capital | $-27,780,000 | $-65,509,000 | $-58,977,000 | $-18,391,000 |
| Change In Other Current Liabilities | $-8,674,000 | $-6,339,000 | $-2,197,000 | $-4,203,000 |
| Change In Payables And Accrued Expense | $-23,377,000 | $-28,844,000 | $4,260,000 | $5,539,000 |
| Change In Accrued Expense | $-20,980,000 | $-25,904,000 | $15,838,000 | $3,336,000 |
| Change In Payable | $-2,397,000 | $-2,940,000 | $-11,578,000 | $2,203,000 |
| Change In Account Payable | $-2,397,000 | $-2,940,000 | $-11,578,000 | $2,203,000 |
| Change In Prepaid Assets | $2,720,000 | $987,000 | $-29,124,000 | $-12,599,000 |
| Change In Inventory | $0 | $-33,795,000 | $-29,647,000 | $0 |
| Change In Receivables | $1,551,000 | $6,606,000 | $-8,674,000 | $0 |
| Changes In Account Receivables | $1,551,000 | $-2,068,000 | $0 | $0 |
| Other Non Cash Items | $8,420,000 | $10,643,000 | $15,168,000 | $6,933,000 |
| Stock Based Compensation | $10,840,000 | $20,971,000 | $34,101,000 | $25,482,000 |
| Asset Impairment Charge | $0 | $3,267,000 | $0 | $0 |
| Amortization Of Securities | $0 | $0 | $-236,000 | $688,000 |
| Depreciation Amortization Depletion | $4,133,000 | $5,468,000 | $6,243,000 | $6,629,000 |
| Depreciation And Amortization | $4,133,000 | $5,468,000 | $6,243,000 | $6,629,000 |
| Depreciation | $4,133,000 | $5,468,000 | $6,243,000 | $6,629,000 |
| Gain Loss On Sale Of PPE | $-192,000 | $317,000 | $0 | $0 |
| Gain Loss On Sale Of Business | $0 | $-146,707,000 | $0 | $0 |
| Net Income From Continuing Operations | $5,696,000 | $136,000 | $-113,724,000 | $-250,157,000 |
| Change In Other Working Capital | - | $-4,124,000 | $6,405,000 | $-7,128,000 |
| Gain Loss On Investment Securities | - | $-546,000 | $-1,554,000 | - |
Fetched: 2026-07-05